Printer Friendly

SCHERER BIOFOR UNIT STARTS HUMAN TESTS OF NEW ARTHRITIS DRUG

 ATLANTA, Nov. 10 /PRNewswire/ -- Scherer Healthcare, Inc. (NASDAQ-NMS: SCHR) said its Biofor, Inc. unit of Waverly, PA, began human testing of BF-389, a novel anti-inflammatory for treating arthritis.
 Biofor officials said preliminary preclinical studies of the investigational drug indicated it is either therapeutically equivalent or superior to the leading marketed non-steroidal anti-inflammatories (NSAIDs), but with a markedly different pharmacological and safety profile. BF-389 is a multiple inhibitor of key (inflammatory) enzymes and inhibits the production of TNF in vitro. In addition, in a published 21 day comparative animal study, BF-389 was shown to have a significant improved safety profile when compared to the leading NSAIDs.
 BF-389 was designed and synthesized with the aid of Biofor's powerful computer technology, MCADD(TM), that enables researchers to pinpoint the specific fragment, or biophore, responsible for a desired therapeutic action. It then screens candidate molecules to eliminate toxicophores responsible for certain toxicity problems prior to further development and human testing.
 The company's drug discovery tools can shave considerable time off the normal drug development cycle and potentially save tens of millions in costs normally encountered to take a drug candidate from the concept stage to a formal filing for U.S. registration.
 Biofor's business strategy is to focus on small organic molecules since they can be dosed orally and are much less expensive to manufacture than protein-based drugs. Other candidates currently under development by Biofor or with partners include products for arthritis, inflammatory bowel disease, psoriasis, BPH, heart disease, and fungal infections.
 In addition to Biofor, Scherer Healthcare also owns and operates businesses in medical sharps disposal, custom medical supplies, and over the counter pharmaceutical products. Recently, Scherer Healthcare completed a transaction which could provide it with up to 65 percent ownership of Marquest Medical Products, Inc. (NASDAQ: MMPI), an international manufacturer and distributor of specialty cardiopulmonary, respiratory, and anesthesia disposal devices.
 -0- 11/10/93
 /CONTACT: Robert D. Tucker, chairman & CEO, or James E. Brands, vice chairman, 404-333-0066 both of Scherer Healthcare; or Dr. Robert W. Naismith, president and CEO of Biofor, 717-586-1333; or Thomas Redington of Redington, Inc., 203-222-7399 or 212-926-1733/
 (SCHR MMPI)


CO: Scherer Healthcare, Inc. ST: Georgia, Pennsylvania IN: MTC SU: PDT

MP-SH -- NY029 -- 2666 11/10/93 10:23 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 10, 1993
Words:371
Previous Article:LANDS' END REPORTS THIRD QUARTER
Next Article:COMMODORE ENVIRONMENTAL SERVICES, INC. ANNOUNCES THIRD QUARTER RESULTS
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters